Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $13.83

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $13.83.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th.

BioCryst Pharmaceuticals Trading Up 2.6 %

NASDAQ BCRX opened at $4.27 on Tuesday. The firm’s 50 day simple moving average is $5.07 and its 200 day simple moving average is $5.52. The firm has a market capitalization of $881.03 million, a price-to-earnings ratio of -3.62 and a beta of 1.90. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $89.19 million. On average, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.69 earnings per share for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 2,388 shares in the last quarter. Teacher Retirement System of Texas raised its holdings in BioCryst Pharmaceuticals by 4.9% in the 3rd quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,519 shares during the last quarter. Fifth Third Bancorp boosted its position in BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the period. Teza Capital Management LLC grew its holdings in BioCryst Pharmaceuticals by 12.8% during the 3rd quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock worth $261,000 after acquiring an additional 4,180 shares during the last quarter. Finally, Great Valley Advisor Group Inc. increased its position in BioCryst Pharmaceuticals by 34.7% in the 3rd quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 4,200 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.